tiprankstipranks
Shattuck Labs Reports Promising Cancer Trial Outcomes
Company Announcements

Shattuck Labs Reports Promising Cancer Trial Outcomes

Don't Miss Our Christmas Offers:

The latest update is out from Shattuck Labs (STTK).

Shattuck Labs, Inc. has shared encouraging preliminary results from its Phase 1B clinical trial, which is evaluating SL-172154 combined with azacitidine in treating patients with high-risk myelodysplastic syndromes and TP53 mutant acute myeloid leukemia. This news, potentially significant for investors and those tracking advancements in cancer therapies, highlights the progress Shattuck Labs is making in its oncology pipeline.

For an in-depth examination of STTK stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskShattuck Labs Focuses on Promising Antibody Development
TheFlyShattuck Labs sees cash runway into 2027
TheFlyShattuck Labs reports Q3 EPS (33c), consensus (42c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App